Compare Abbott Laboratories (ABT) vs Vanguard Total International Bond Index Fund ETF (BNDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs Vanguard Total International Bond Index Fund ETF — how do they compare? Abbott Laboratories trades at $111.03 (market cap $187.95B), while Vanguard Total International Bond Index Fund ETF trades at $47.83. The key difference: Abbott Laboratories pays a 2.32% dividend while Vanguard Total International Bond Index Fund ETF pays none, and Abbott Laboratories is trading nearer its 52-week high, Vanguard Total International Bond Index Fund ETF nearer its low. Which is the better fit depends on your goals.
| ABT | BNDX | |
|---|---|---|
Market Cap | $187.95B | — |
Sector | Health | — |
52-Week High | $136.62 | $49.91 |
52-Week Low | $82.57 | $47.57 |
Enterprise Value | $214.96B | — |
Dividend Yield | 2.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.
Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.
BNDX trades at $47.91, up 0.25% with neutral technical signals. The ETF shows mixed institutional activity with Apella Capital reducing holdings by 3.0% while Archer Investment increased by 48.2% in Q2 2026. Recent dividend payments of $0.11-$0.12 provide income appeal, though key valuation ratios remain unavailable for analysis.
Outlook remains balanced amid bond market volatility. Rising Treasury yields and inflation concerns create headwinds, while institutional interest and steady dividends offer support. The ETF's international bond exposure provides diversification benefits but remains sensitive to global interest rate movements and geopolitical tensions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Vanguard Total International Bond Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the Bloomberg Global Aggregate ex-USD Float Adjusted RIC Capped Index (USD Hedged). This index provides a broad-based measure of the global, investment-grade, fixed-rate debt markets. It is non-diversified.
Read more on BNDX →
